菌状息肉腫治療法の世界市場予測・分析2019-2023

◆英語タイトル:Mycosis Fungoides Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32050
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、菌状息肉腫治療法の世界市場について調べ、菌状息肉腫治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、菌状息肉腫治療法の市場規模をセグメンテーション別(種類別(小分子、生物製剤)、)と地域別(グローバル)に分けて算出しました。Technavio社は菌状息肉腫治療法の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・菌状息肉腫治療法の市場状況
・菌状息肉腫治療法の市場規模
・菌状息肉腫治療法の市場予測
・菌状息肉腫治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(小分子、生物製剤)
・菌状息肉腫治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Mycosis Fungoides Therapeutics Market: About this market

Technavio’s mycosis fungoides therapeutics market analysis considers sales from small molecules and biologics types. Our analysis also considers the sales of mycosis fungoides therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost and easy availability of small molecules will play a significant role in the small molecules segment to maintain its market position. Also, our global mycosis fungoides therapeutics market report looks at factors such as special drug designations, recent drug approvals, and growing incidence of mycosis fungoides. However, slow progressive nature of the disease, dominance of alternative therapies, and stringent regulatory policies may hamper the growth of the mycosis fungoides therapeutics industry over the forecast period.

Global Mycosis Fungoides Therapeutics Market: Overview

Special drug designations

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. Most of the drugs being developed for the treatment of mycosis fungoides have been receiving special designations from regulatory bodies such as the US FDA and the EMA. Many of these drugs have received designations such as the Orphan drug designation and Breakthrough Therapy designation. Vendors who have received the Orphan drug designation for their drugs get certain regulatory and tax benefits. Similarly, the Breakthrough Therapy designation is granted by the US FDA to drugs that have displayed a superior efficacy and substantial treatment advantages over other drugs that are currently available in the market for the treatment of the same indication. Breakthrough therapy designation also confers vendors with a priority review status over other drugs that are being evaluated by the regulatory body. These factors will contribute to an increase in the sales of drugs to treat mycosis fungoides, fueling the mycosis fungoides therapeutics market to grow at a CAGR of over 6% during the forecast period.

Strong R&D of pipeline molecules

Various pharmaceutical and biotechnology companies are conducting research on developing therapeutics to capture the unmet need for highly effective therapeutics that can either provide long-term relief from the indication or cure the indication. To increase the customer base and remain competitive, vendors are developing highly effective biologics, targeted therapies, and small molecule-based therapies. As a result, the mycosis fungoides therapeutics market has been recording strong R&D of pipeline molecules. The expected launch of biologics will shift the therapeutic landscape for mycosis fungoides toward biologics, contributing to mycosis fungoides therapeutics market growth.

For the detailed list of factors that will drive the global mycosis fungoides therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global mycosis fungoides therapeutics market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading mycosis fungoides therapeutics manufacturers, that include Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence the market growth. This is to help companies strategize and leverage on all the forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Small molecules – Market size and forecast 2018-2023

Biologics – Market size and forecast 2018-2023

Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Strong R&D of pipeline molecules

Novel drug delivery system

Increasing research funding

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Azurity Pharmaceuticals Inc.

Celgene Corp.

Eisai Co. Ltd.

Helsinn Healthcare SA

Horizon Therapeutics Plc

Kyowa Kirin Co. Ltd.

Merck & Co. Inc.

Seattle Genetics Inc.

Soligenix Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market characteristics analysis

Exhibit 06: Market segments

Exhibit 07: Market definition – Inclusions and exclusions checklist

Exhibit 08: Market size 2018

Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 11: Five forces analysis 2018

Exhibit 12: Five forces analysis 2023

Exhibit 13: Bargaining power of buyers

Exhibit 14: Bargaining power of suppliers

Exhibit 15: Threat of new entrants

Exhibit 16: Threat of substitutes

Exhibit 17: Threat of rivalry

Exhibit 18: Market condition – Five forces 2018

Exhibit 19: Global mycosis fungoides therapeutics market pipeline: Overview

Exhibit 20: Global mycosis fungoides therapeutics market pipeline: Snapshot

Exhibit 21: Type – Market share 2018-2023 (%)

Exhibit 22: Comparison by type

Exhibit 23: Small molecules – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 25: Biologics – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 27: Market opportunity by type

Exhibit 28: Customer landscape

Exhibit 29: Customer landscape analysis

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Decision framework

Exhibit 47: Impact of drivers and challenges

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendor landscape analysis

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Azurity Pharmaceuticals Inc. – Vendor overview

Exhibit 55: Azurity Pharmaceuticals Inc. – Business segments

Exhibit 56: Azurity Pharmaceuticals Inc. – Organizational developments

Exhibit 57: Azurity Pharmaceuticals Inc. – Key offerings

Exhibit 58: Azurity Pharmaceuticals Inc. – Key customers

Exhibit 59: Celgene Corp. – Vendor overview

Exhibit 60: Celgene Corp. – Business segments

Exhibit 61: Celgene Corp. – Organizational developments

Exhibit 62: Celgene Corp. – Geographic focus

Exhibit 63: Celgene Corp. – Key offerings

Exhibit 64: Celgene Corp. – Key customers

Exhibit 65: Eisai Co. Ltd. – Vendor overview

Exhibit 66: Eisai Co. Ltd. – Business segments

Exhibit 67: Eisai Co. Ltd. – Organizational developments

Exhibit 68: Eisai Co. Ltd. – Geographic focus

Exhibit 69: Eisai Co. Ltd. – Segment focus

Exhibit 70: Eisai Co. Ltd. – Key offerings

Exhibit 71: Eisai Co. Ltd. – Key customers

Exhibit 72: Helsinn Healthcare SA – Vendor overview

Exhibit 73: Helsinn Healthcare SA – Business segments

Exhibit 74: Helsinn Healthcare SA – Organizational developments

Exhibit 75: Helsinn Healthcare SA – Key offerings

Exhibit 76: Helsinn Healthcare SA – Key customers

Exhibit 77: Horizon Therapeutics Plc – Vendor overview

Exhibit 78: Horizon Therapeutics Plc – Business segments

Exhibit 79: Horizon Therapeutics Plc – Organizational developments

Exhibit 80: Horizon Therapeutics Plc – Geographic focus

Exhibit 81: Horizon Therapeutics Plc – Segment focus

Exhibit 82: Horizon Therapeutics Plc – Key offerings

Exhibit 83: Horizon Therapeutics Plc – Key customers

Exhibit 84: Kyowa Kirin Co. Ltd. – Vendor overview

Exhibit 85: Kyowa Kirin Co. Ltd. – Business segments

Exhibit 86: Kyowa Kirin Co. Ltd. – Organizational developments

Exhibit 87: Kyowa Kirin Co. Ltd. – Geographic focus

Exhibit 88: Kyowa Kirin Co. Ltd. – Segment focus

Exhibit 89: Kyowa Kirin Co. Ltd. – Key offerings

Exhibit 90: Kyowa Kirin Co. Ltd. – Key customers

Exhibit 91: Merck & Co. Inc. – Vendor overview

Exhibit 92: Merck & Co. Inc. – Business segments

Exhibit 93: Merck & Co. Inc. – Organizational developments

Exhibit 94: Merck & Co. Inc. – Geographic focus

Exhibit 95: Merck & Co. Inc. – Segment focus

Exhibit 96: Merck & Co. Inc. – Key offerings

Exhibit 97: Merck & Co. Inc. – Key customers

Exhibit 98: Seattle Genetics Inc. – Vendor overview

Exhibit 99: Seattle Genetics Inc. – Business segments

Exhibit 100: Seattle Genetics Inc. – Organizational developments

Exhibit 101: Seattle Genetics Inc. – Key offerings

Exhibit 102: Seattle Genetics Inc. – Key customers

Exhibit 103: Soligenix Inc. – Vendor overview

Exhibit 104: Soligenix Inc. – Business segments

Exhibit 105: Soligenix Inc. – Organizational developments

Exhibit 106: Soligenix Inc. – Segment focus

Exhibit 107: Soligenix Inc. – Key offerings

Exhibit 108: Soligenix Inc. – Key customers

Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 115: Validation techniques employed for market sizing

Exhibit 116: List of abbreviations

Exhibit 117: Definition of market positioning of vendors



【掲載企業】

Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., and Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[菌状息肉腫治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆